{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"51.9","upperLimit":"64.1","value":"58.1"},{"groupId":"OG001","lowerLimit":"41.4","upperLimit":"53.7","value":"47.5"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"265"},{"groupId":"OG001","value":"265"}],"units":"Participants"}],"description":"Response rate of participants with complete remission (CR), or marrow remission (mCR), or partial remission (PR), or hematologic improvement (HI).\n\nCR: where the Bone marrow: ≤ 5% blasts with normal maturation of all cell lineages and Peripheral blood: where Hgb ≥ 10 g/dL AND Platelets ≥ 100\\*109/L AND Neutrophils ≥ 1.0\\*109/L AND Peripheral blasts 0%.\n\nmCR: Bone marrow: ≤ 5% blasts and blast count decrease by ≥ 50% compared to baseline; Peripheralblood/transfusion: Marrow CR may be achieved with or without improved blood counts or with or without transfusions PR: All CR criteria except bone marrow: ≥50% decrease from baseline in blasts in bone marrow AND blast count in bone marrow \\>5%.\n\nHI: restoration or enhancement of the function of the body's blood cell-producing system that must last as least 8 weeks.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants were randomized to sabatolimab plus Azacitidine","id":"OG000","title":"Sabatolimab (MBG453) + Azacitidine"},{"description":"Participants were randomized to placebo plus Azacitidine","id":"OG001","title":"Placebo + Azacitidine"}],"paramType":"NUMBER","populationDescription":"FAS comprised of all participants to whom study treatment had been assigned by randomization.","reportingStatus":"POSTED","timeFrame":"up to approx. 52 months","title":"Percentage of Participants With Either CR, or mCR, or PR, or HI in Each Treatment Arm According to International Working Group for MDS (IWG-MDS) as Per Investigator Assessment","type":"SECONDARY","unitOfMeasure":"Percentage of participants"}